Hovid: Manufacturing licence for Chemor plant reinstated

PETALING JAYA: One of Hovid Bhd’s manufacturing licences has been reinstated, while another is expected to be granted by the end of May, pending the completion of corrective actions by the company.
Recall that Hovid’s manufacturing licences were revoked by the Health Ministry’s Pharmaceutical Services Division following an audit conducted by the National Pharmaceutical Regulatory Agency (NPRA) in January that revealed its non-compliance with the latest Current Good Manufacturing Practice (cGMP) requirements.
The company told Bursa Malaysia that it has just received the manufacturing licence for its Chemor, Perak, plant from the National Pharmaceutical Control Bureau of the Health Ministry. The licence is valid from March 6, 2017, and is be renewed three months prior to the expiry date on Dec 31, 2017.
For the Ipoh plant, Hovid said it is targeting to complete the necessary corrective actions to comply with the cGMP by the end of this month.
“The reissuance of the licence will be subject to NPRA being satisfied with our corrective actions taken. We estimate we’ll receive the decision from NPRA for our Ipoh plant by end of May 2017,” it noted.
Necessary reports will have to be submitted thereafter.
Hovid said it has implemented increased measures in ensuring stringent controls for the GMP processes in order to have its Chemor plant’s licence reinstated.